Table 1 Frequency of the patients’ clinicopathological characteristics (sex, age, KPS, disease stage at start of first-line chemotherapy, type of first-line chemotherapy, tumour grade and number of metastatic sites) and correlation with corresponding overall and progression-free survival
n | OS (months) | P (log-rank) | HR | 95% CI | PFS (months) | P (log-rank) | HR | 95% CI | |
|---|---|---|---|---|---|---|---|---|---|
Sex | |||||||||
Male | 79 | 8.3 | 0.852 | 0.966 | 0.668–1.395 | 7.0 | 0.681 | 1.094 | 0.712–1.681 |
Female | 55 | 7.3 | 4.7 | ||||||
Age group | |||||||||
<60 years | 54 | 8.3 | 0.348 | 1193 | 0.825–1.725 | 6.8 | 0.682 | 1.094 | 0.712–1.681 |
⩾60 years | 80 | 7.9 | 7.0 | ||||||
KPS | |||||||||
⩽80 | 51 | 6.7 | 0.025 | 1537 | 1.051–2.249 | 4.6 | 0.062 | 1.509 | 0.976–2.332 |
>80 | 83 | 10.6 | 7.6 | ||||||
Stage at start of palliative CTX | |||||||||
Locally advanced | 14 | 12.0 | 0.103 | 1705 | 0.89–3.265 | 10.0 | 0.111 | 1.795 | 0.864–3.729 |
Metastatic | 120 | 8.0 | 6.8 | ||||||
First-line CTX, CTX type | |||||||||
Gemcitabine-based | 112 | 8.3 | 0.064 | 1552 | 0.970–2.482 | 7.4 | 0.006 | 2.111 | 1.226–3.635 |
Fluoropyrimidine-based | 22 | 7.2 | 4.0 | ||||||
Tumour grade | |||||||||
G1–G2 | 54 | 9.2 | 0.243 | 1246 | 0.861–1.802 | 8.7 | 0.123 | 1.405 | 0.910–2.169 |
G3–G4 | 80 | 7.9 | 6.6 | ||||||
Metastatic sites | |||||||||
0 | 14 | 12.0 | 0.220 | 1281 | 0.945–1.737 | 10.0 | 0.084 | 1,509 | 1.049–2.170 |
1 | 84 | 8.3 | 7.0 | ||||||
>1 | 36 | 7.3 | 5.5 | ||||||
